Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Calliditas Therapeutics AB (publ) (LC8.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
8.88-0.24 (-2.63%)
At close: 09:15AM CET
Advertisement
Full screen
Loading interactive chart...
  • Zacks

    New Strong Sell Stocks for January 6th

    CALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023.

  • PR Newswire

    China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

    Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for the New Drug Application (NDA) of Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression.

  • PR Newswire

    Number of shares and votes in Calliditas Therapeutics

    During December, Calliditas Therapeutics AB (publ) has issued 415,000 common shares connected to the company's long term incentive program 2019/2022. Thus, as of December 30, 2022, the number of shares and votes in the company amounts to 59,572,587 shares and 59,572,587 votes.

Advertisement
Advertisement